Recently, we discovered patients with inherited adenosine deaminase (ADA) deficiency are predisposed to pulmonary alveolar proteinosis (PAP). PAP is characterized by the accumulation of surfactant in the alveoli. To overcome ethical issues and limited patient samples, animal models are often utilized. Here, I investigated the lung abnormalities in ADA deficient (ADA -/-) mice, which suffer from severe hypoxia, till their death at 3 weeks. I hypothesized that, similar to ADA-deficient patients, ADA -/- mice demonstrate evidence of PAP. Indeed, electron microscopy showed thickening of type I cells, accumulation of apoptotic foamy alveolar macrophages, cholesterol and lipoproteinaceous material that is periodic-acid Schiff (PAS) positive and diagnostic of PAP. Moreover, the pulmonary abnormalities were corrected with supplementation of ADA. In conclusion, we demonstrated evidence of PAP in ADA -/- mice for the first time and their suitability to study pathogenesis of PAP in ADA deficiency.

Recently, we discovered patients with inherited adenosine deaminase (ADA) deficiency are predisposed to pulmonary alveolar proteinosis (PAP). PAP is characterized by the accumulation of surfactant in the alveoli. To overcome ethical issues and limited patient samples, animal models are often utilized. Here, I investigated the lung abnormalities in ADA deficient (ADA -/-) mice, which suffer from severe hypoxia, till their death at 3 weeks. I hypothesized that, similar to ADA-deficient patients, ADA -/- mice demonstrate evidence of PAP. Indeed, electron microscopy showed thickening of type I cells, accumulation of apoptotic foamy alveolar macrophages, cholesterol and lipoproteinaceous material that is periodic-acid Schiff (PAS) positive and diagnostic of PAP. Moreover, the pulmonary abnormalities were corrected with supplementation of ADA. In conclusion, we demonstrated evidence of PAP in ADA -/- mice for the first time and their suitability to study pathogenesis of PAP in ADA deficiency.

Interleukin (IL) -7 is an essential non-redundant cytokine that influences T-cell differentiation, proliferation, homeostasis and T-cell functions. In T-cells, IL-7 signals are transduced via IL-7's heterodimeric receptor composed of a common, γ chain (CD132) and an IL-7 specific, α chain (CD127). In light of the many roles that IL-7 plays in T-cell biology, it is no surprise that CD127 expression is tightly regulated in T-cells. In this study, I explore the effects that disease specific mutations in CD127 have on CD127 expression, regulation and signal transduction using an in vitro T-cell model. Here I specifically examined four disease associated mutations of CD127: P132S associated with severe combined immunodeficiency; L242_L243insNPC associated with T-cell acute lymphoblastic leukemia; I356V & T244I associated with autoimmune diseases like multiple sclerosis, rheumatoid arthritis and type 1 diabetes. In developing my model, I decided to use Jurkat cells because they expressed high endogenous surface levels of CD132, low endogenous surface levels of CD127 and endogenous STAT5. Jurkat cells were transduced with lentiviruses that induced expression of either WT or one of the four mutant CD127. I found that transduced Jurkat cells produced the WT and all four mutant CD127 proteins. I also found that wild type CD127, I356V, L242_L243insNPC and T244I mutant CD127 proteins were all expressed at the same level on the cell surface. However, I could not detect P132S mutated CD127 protein in its native state on the surface or intracellularly. I also found no differences between the mutant CD127 and wild type CD127 with regards to the level of soluble CD127 transcripts. I found that cell lines expressing L242_L243insNPC, I356V and T244I mutant CD127 protein, down-regulated surface CD127 at high IL-7 doses (25ng/mL) to the same extent as in the cell line expressing wild type CD127 protein. Interestingly, at the low IL-7 dose (1ng/mL) these mutant CD127 cell lines down-regulated surface CD127 to a lesser degree the wild type CD127 cell line. Further studies are required to elucidate whether P132S mutated CD127 is expressed on the surface and if T224I and I356V mutations in CD127 enhance signaling. By understanding CD127 dysregulation and dysfunction in disease states, we can potentially develop therapeutics that can return the function of CD127 to normalcy.

Des mutations gains de fonction du gène STING chez l’Homme (telles que V155M) déclenchent une pathologie autoinflammatoire sévère de type interféronopathie, le SAVI (Sting associated vasculopathy with onset in infancy), une vasculopathie associée à une fibrose pulmonaire et des symptômes lupus-like. Afin de comprendre la physiopathologie du SAVI, nous avons généré un modèle murin porteur de la mutation correspondante grâce à la technologie CRISPR/Cas9. Ces souris STING V154M/WT développent un phénotype SCID (déficit immunitaire combiné sévère) avec diminution des LT, des LB et des NK en périphérie, et une expansion du compartiment myéloïde. Ce défaut de développement est observé précocement dès le stade pré-proB dans la moelle osseuse, et au stade DN2 dans le thymus, et semble intrinsèque aux cellules hématopoïétiques. De plus, ces souris présentent une hypogammaglobulinémie sévère. Les LT et LB matures présentent également des défauts intrinsèques. Enfin, les souris présentent une signature IFN, mais leur phénotype SCID est IFN de type I-indépendant. Ces résultats mettent en évidence un rôle important de STING dans le développement lymphoïde. / In humans, point mutations in STING gene, such as V155M, lead to a severe autoinflammatory disease called SAVI (Sting associated vasculopathy with onset in infancy), classified as interferonopathy and characterized by vasculopathy, pulmonary fibrosis and a lupus-like pathology. In order to better understand the pathophysiology of SAVI, we generated a mouse model with the corresponding mutation, using CRISPR/Cas9 technology. These STING V154M/WT mice develop a SCID (severe combined immunodeficiency disease) with decrease of peripheral T, B and NK cells, and expansion of myeloid compartment. This defect seems to be present since the early stages, i.e. pre-proB cells stage in bone marrow and DN2 stage in thymus, and seems intrinsic to hematopoiectic cells. In addition, these mice present a strong hypogammaglobulinemia. Mature T and B cells also present intrinsic defaults. Finally, these mice present an IFN signature but their phenotype is independent of the IFN pathway. These results highlight an important role of STING in lymphoid development.

Ein durch „Ca2+ Release Activated Ca2+ (CRAC)“-Kanal vermittelter Ca2+-Einstrom ist unverzichtbar für die vollständige Aktivierung von T-Zellen und eine produktive Immunantwort. Im Jahr 2006 führte die Entdeckung des transmembranen Proteins Orai1, einer porenbildenden Untereinheit des CRAC-Kanals, zu einem besseren Verständnis dieses Signalweges. Eine Mutation in Orai1 hat durch die Aufhebung der CRAC-Kanal Funktion eine schwere kombinierte Immundefizienz (SCID) zur Folge (Feske, S. et al. 2006). Die im Rahmen dieser Arbeit präsentierten Experimente hatten die nähere Erforschung der Rolle von Orai1 in Bezug auf die Aktivierung und Entwicklung von Lymphozyten sowie auf die pathogenetische Bedeutung für humane Immundefektsyndrome zum Ziel. So konnte hier durch das Sequenzieren genomischer DNA mehrerer SCID-Patienten eine neue Mutation in Orai1 aufgedeckt werden. Mithilfe intrazellulärer Durchflusszytometrie und Real-Time-PCR gelang es, die Expression von Orai1 auf humanen und murinen Immunzellen, einschließlich T- und B-Lymphozyten, nachzuweisen. Darüber hinaus wurden Orai1 „knock-in“ Mäuse analysiert, welche transgen für eine bei zwei SCID-Patienten gefundene Mutation (R91W) (Feske, S. et al. 2006) sind. Dadurch war es möglich die Funktion von Orai1 und die des CRAC-Kanal vermittelten Ca2+-Einstroms für die Entwicklung und Aktivierung von Lymphozyten zu analysieren. Diese transgenen Mäuse stellen das zu diesem Zeitpunkt erste Tiermodell dar, mit dessen Hilfe die Rolle von CRAC-Kanälen in vivo studiert werden kann.

Thesis (Ph. D.)--University of Missouri--Columbia, 2005. / "May 2005." Typescript. Vita. Includes bibliographical references (leaves 125-147). Also issued on the Internet.

No description available.

The course of microsporidiosis caused by Encephalitozoon cuniculi in immunocompetent BALB/c mice and immunodeficient SCID mice was screened using molecular methods. The site of infection in organs was located using molecular and histology methods. The effectiveness of albendazole treatement and possibility of infection relapse after immunosuppresion (cyclosporine A, tacrolimus, mycofenolate mofetil) was also studied. Moreover, the course of excretion of microsporidial spores in feces was monitored during the whole time of experiment.

Ein durch „Ca2+ Release Activated Ca2+ (CRAC)“-Kanal vermittelter Ca2+-Einstrom ist unverzichtbar für die vollständige Aktivierung von T-Zellen und eine produktive Immunantwort. Im Jahr 2006 führte die Entdeckung des transmembranen Proteins Orai1, einer porenbildenden Untereinheit des CRAC-Kanals, zu einem besseren Verständnis dieses Signalweges. Eine Mutation in Orai1 hat durch die Aufhebung der CRAC-Kanal Funktion eine schwere kombinierte Immundefizienz (SCID) zur Folge (Feske, S. et al. 2006). Die im Rahmen dieser Arbeit präsentierten Experimente hatten die nähere Erforschung der Rolle von Orai1 in Bezug auf die Aktivierung und Entwicklung von Lymphozyten sowie auf die pathogenetische Bedeutung für humane Immundefektsyndrome zum Ziel. So konnte hier durch das Sequenzieren genomischer DNA mehrerer SCID-Patienten eine neue Mutation in Orai1 aufgedeckt werden. Mithilfe intrazellulärer Durchflusszytometrie und Real-Time-PCR gelang es, die Expression von Orai1 auf humanen und murinen Immunzellen, einschließlich T- und B-Lymphozyten, nachzuweisen. Darüber hinaus wurden Orai1 „knock-in“ Mäuse analysiert, welche transgen für eine bei zwei SCID-Patienten gefundene Mutation (R91W) (Feske, S. et al. 2006) sind. Dadurch war es möglich die Funktion von Orai1 und die des CRAC-Kanal vermittelten Ca2+-Einstroms für die Entwicklung und Aktivierung von Lymphozyten zu analysieren. Diese transgenen Mäuse stellen das zu diesem Zeitpunkt erste Tiermodell dar, mit dessen Hilfe die Rolle von CRAC-Kanälen in vivo studiert werden kann.

Le Cancer Colo Rectal (CCR) est la deuxième cause de mortalité par cancer dans le monde. Le risque de récidive après traitement curatif atteint 45% pour les stades 3. Une des hypothèses à l’heure actuelle pouvant expliciter le processus métastatique et les récidives est la présence en son sein de cellules « souches », pouvant « initier » le cancer. Notre réflexion s’inscrit dans la continuité des travaux réalisés au sein de notre Laboratoire, intitulés «Stratégies d’isolement et de caractérisation des cellules initiatrices de cancer colorectal», (Mélin et al, 2012). Dans une première partie, notre travail a porté sur l’analyse in vitro de la sensibilité des fractions enrichies en CIC aux différentes molécules de chimiothérapie les plus couramment utilisées en cancérologie colorectale.Puis, dans une deuxième partie, l’analyse des tumeurs obtenues après greffe a été faite ex ovo sur la Membrane Chorio-Allantoïdienne d’embryon de poulet (CAM), modèle facilement manipulable, peu onéreux et très rapide. Ce modèle étant naturellement immunodéprimé, il permet d’obtenir des informations concernant les phénomènes clés de la tumorigénèse et de la néoangiogénèse. Des analyses de la croissance tumorale, de l’histologie (prolifération, apoptose et vascularisation) et des analyses protéiques ont été menées en parallèle. De cette dernière étude, un marqueur particulier la E cadhérine, a été mis en évidence comme témoin indirect d’agressivité. En effet, au sein des tumeurs obtenues à partir de F1 HCT116, fraction himiosensible, l’expression de la E cadhérine est augmentée contrairement aux tumeurs obtenues à partir de F3 WiDr, fraction chimiorésistante, montrant une diminution d’expression de la E cadhérine.Ainsi, dans une troisième partie, sachant qu’un lien entre cellules initiant le cancer et E cadhérine a été mis en évidence, nous nous sommes focalisés sur son expression. Nous avons alors étudié son expression in vitro sur des cellules résistantes au 5 Fluorouracile. Puis, son expression a été étudiée ex vivo au sein de tissus et de sérums de patients opérés de cancer colorectal. / The ColoRectal Cancer (CCR) is the second leading cause of cancer mortality in the world. The risk of recurrence after curative treatment reaches 45% for stages 3. One of the hypotheses currently able to explain the metastatic process and the recurrences is the presence within it of "stem" cells, which can "initiate" the cancer. Our reflection is in line with the work carried out in our Laboratory, entitled "Strategies for the isolation and characterization of cells that initiate colorectal cancer" (Mélin et al, 2012).In the first part, our work focused on in vitro analysis of the sensitivity of fractions enriched in CIC to different chemotherapy molecules most commonly used in colorectal cancer (CRC). Then, in a second part, the analysis of the tumors obtained after transplantation was made ex ovo on Chicken Embryo Chorio-Allantoid Membrane (CAM), an easily manipulated model, inexpensive and very fast. This model provides information on the key phenomena of tumorigenesis and neoangiogenesis. Analyzes of tumor growth, histology (proliferation, apoptosis and vascularization) and protein analyzes were carried out in parallel. From this last study, a particular marker, E cadherin, was highlighted as an indirect link with witness of aggressiveness. Indeed, within the tumors obtained from F1 HCT116, the chemosensitive fraction, the expression of cadherin E was increased in contrast to the tumors obtained from F3 WiDr, chemoresistant fraction, showing a decrease in expression of E cadherin.Thus, in a third part, knowing that a link between cells initiating cancer and E cadherin was highlighted, we focused on its expression. We first studied its expression in vitro on 5 Fluorouracilresistant cells. Its expression was then studied ex vivo in tissues and sera of operated patients of CRC.